SCHEMBL4380442

SCHEMBL4380442

COc1cc2nccc(Oc3ccc4nc(NC(=O)c5ccc(Cl)cc5Cl)sc4c3)c2cc1OC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 2/20 0.64
KDR P35968 14/20 0.61
AURKB Q96GD4 2/20 0.61
DCLK1 O15075 1/20 0.61
FES P07332 1/20 0.61
PIM1 P11309 1/20 0.61
CDK2 P24941 1/20 0.61
GSK3A P49840 1/20 0.61
GSK3B P49841 1/20 0.61
IRAK1 P51617 1/20 0.61
MAP4K2 Q12851 1/20 0.61
NTRK3 Q16288 1/20 0.61
HIPK4 Q8NE63 1/20 0.61
CLK4 Q9HAZ1 1/20 0.61
STK17A Q9UEE5 1/20 0.61
MAP4K5 Q9Y4K4 1/20 0.61
CSNK1G3 Q9Y6M4 1/20 0.61
AURKA O14965 1/20 0.57
LCK P06239 1/20 0.57
CSF1R P07333 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4373514 0.91 MET (0.70) METKDRAURKBGSK3AGSK3B
SCHEMBL4372566 0.89 MET (0.67) METKDRAURKBDCLK1FES
SCHEMBL4370671 0.87 MET (0.66) METKDRAURKBAURKALCK
SCHEMBL4368363 0.87 MET (0.66) METKDRAURKBDCLK1FES
SCHEMBL4370355 0.86 MET (0.73) METKDRAURKBAURKALCK
SCHEMBL13587143 0.85 MET (0.67) METKDRAURKBAURKALCK
SCHEMBL13587175 0.85 MET (0.62) METKDRAURKBDCLK1FES
SCHEMBL13587151 0.85 MET (0.64) METKDRAURKBDCLK1FES
SCHEMBL13587167 0.85 MET (0.66) METKDRAURKBDCLK1FES
SCHEMBL4373376 0.85 MET (0.66) METKDRAURKBAURKALCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7626030-B2 Compounds and methods of use AMGEN INC. (US) 2009-12-01 US disclosed
US-7626030-B2 Compounds and methods of use AMGEN INC. (US) 2009-12-01 US disclosed
US-7626030-B2 Compounds and methods of use AMGEN INC. (US) 2009-12-01 US disclosed
US-20050245547-A1 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma AMGEN INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245547-A1 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma HGF, MET, HGFAC MET 2/4885KDR 90/4885AURKB 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.